Hua Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hua Wang has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Lei Gao
Department of Tuberculosis, Anhui Provincial Chest Hospital (Anhui Institute of Tuberculosis Control), Hefei, Anhui, 230022, People's Republic of China
3 shared publicationsPeng-Fei Huang
Department of Tuberculosis, Anhui Provincial Chest Hospital (Anhui Institute of Tuberculosis Control), Hefei, Anhui, 230022, People's Republic of China
3 shared publicationsShuang Liu
Department of Tuberculosis, Anhui Provincial Chest Hospital (Anhui Institute of Tuberculosis Control), Hefei, Anhui, 230022, People's Republic of China
3 shared publicationsYa-Xue Liang
Department of Tuberculosis, Anhui Provincial Chest Hospital (Anhui Institute of Tuberculosis Control), Hefei, Anhui, 230022, People's Republic of China
3 shared publicationsYan-Jun Xiong
Department of Tuberculosis, Anhui Provincial Chest Hospital (Anhui Institute of Tuberculosis Control), Hefei, Anhui, 230022, People's Republic of China
3 shared publicationsYu Xiao
Department of Tuberculosis, Anhui Provincial Chest Hospital (Anhui Institute of Tuberculosis Control), Hefei, Anhui, 230022, People's Republic of China
3 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-10
Safety and Effectiveness of Contezolid versus Linezolid in Drug-Resistant Tuberculosis: A 12-Month Retrospective Study from China
Background: Contezolid (CZD), a novel oxazolidinone, is a promising therapeutic option for the treatment of Mycobacterium tuberculosis. However, clinical evidence of its safety and efficacy in managing drug-resistant tuberculosis (DR-TB) remains limited. Methods: A retrospective analysis was performed on 135 patients with DR-TB treated at Anhui Chest Hospital between January 2022 and September 2024, including 27 on CZD-based regimens and 108 on linezolid (LZD)-based regimens. Drug-related adverse events (AEs), including bone marrow suppression, peripheral neuropathy, optic neuritis, and gastrointestinal reactions, were systematically recorded. Therapeutic efficacy was comprehensively evaluated based on clinical symptoms, radiological findings, and microbiological results. The 12-month safety and efficacy of the two regimens in DR-TB were assessed. Results: The incidence of AEs in the LZD group reached 54.63%, significantly higher than the 3.7% observed in the CZD group (χ2 = 22.69, P < 0.001). Notably, the rates of bone marrow suppression and peripheral neuropathy in the LZD group were 22.22% and 27.78%, respectively, whereas no such AEs were reported in the CZD group (P = 0.004; P < 0.001, respectively). Regarding efficacy, CZD and LZD showed comparable outcomes in patients with DR-TB (P = 0.491). Conclusion: CZD may have clinical efficacy comparable to LZD in treating DR-TB, while appearing to offer an improved safety profile, notably in reducing bone marrow suppression and peripheral neuropathy.
- 1 March 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-10
Open AccessSafety and Effectiveness of Contezolid versus Linezolid in Drug-Resistant Tuberculosis: A 12-Month Retrospective Study from China
Background: Contezolid (CZD), a novel oxazolidinone, is a promising therapeutic option for the treatment of Mycobacterium tuberculosis. However, clinical evidence of its safety and efficacy in managing drug-resistant tuberculosis (DR-TB) remains limited. Methods: A retrospective analysis was performed on 135 patients with DR-TB treated at Anhui Chest Hospital between January 2022 and September 2024, including 27 on CZD-based regimens and 108 on linezolid (LZD)-based regimens. Drug-related adverse events (AEs), including bone marrow suppression, peripheral neuropathy, optic neuritis, and gastrointestinal reactions, were systematically recorded. Therapeutic efficacy was comprehensively evaluated based on clinical symptoms, radiological findings, and microbiological results. The 12-month safety and efficacy of the two regimens in DR-TB were assessed. Results: The incidence of AEs in the LZD group reached 54.63%, significantly higher than the 3.7% observed in the CZD group (χ2 = 22.69, P < 0.001). Notably, the rates of bone marrow suppression and peripheral neuropathy in the LZD group were 22.22% and 27.78%, respectively, whereas no such AEs were reported in the CZD group (P = 0.004; P < 0.001, respectively). Regarding efficacy, CZD and LZD showed comparable outcomes in patients with DR-TB (P = 0.491). Conclusion: CZD may have clinical efficacy comparable to LZD in treating DR-TB, while appearing to offer an improved safety profile, notably in reducing bone marrow suppression and peripheral neuropathy.
- Open Access
- 18 December 2025
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 15, 1635870
Nutritional status affects inflammatory responses and exacerbates the severity of pulmonary tuberculosis
Purpose: This study aimed to comprehensively assess the impact of nutritional status and inflammatory response on the severity of pulmonary tuberculosis (PTB). Methods: Hospitalized patients with active PTB were included. Severe PTB was defined as active PTB with ≥3 infected lobes on chest imaging. Nutritional status was determined by the geriatric nutritional risk index (GNRI) and prognostic nutritional index (PNI). Inflammatory markers included monocyte-to-lymphocyte ratio (MLR), neutrophil-to-lymphocyte ratio (NLR), and systemic inflammatory response index (SII). Multivariate logistic regression, receiver operating characteristic (ROC) curves, random forest, and mediation analysis were leveraged to clarify the links of nutritional status and inflammatory response with PTB severity. Results: 337 patients were included. In the fully-adjusted logistic regression model, GNRI (OR: 0.93; 95%CI: 0.90-0.96, P<0.001) and PNI (OR: 0.90; 95%CI; 0.86-0.95, P<0.001) were independent protective factors for severe PTB, whereas NLR (OR: 1.07; 95%CI: 1.01-1.16, P<0.05) and MLR (OR: 3.11; 95%CI: 1.16-9.71, P0.05). GNRI mediated 51.64% and 60.58% of the effect of NLR and MLR on PTB, respectively. PNI mediated 70.15% and 76.70% of the effect of NLR and MLR on PTB, respectively. When NLR, MLR, GNRI, and PNI were integrated with traditional clinical indexes, the AUC increased to 0.723 (95% CI: 0.668-0.777). Conclusion: Nutrition and inflammatory response are significantly associated with PTB severity, and nutritional status mediates the effect of inflammatory response on PTB severity.
- 18 December 2025
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 15, 1635870
Open AccessNutritional status affects inflammatory responses and exacerbates the severity of pulmonary tuberculosis
Purpose: This study aimed to comprehensively assess the impact of nutritional status and inflammatory response on the severity of pulmonary tuberculosis (PTB). Methods: Hospitalized patients with active PTB were included. Severe PTB was defined as active PTB with ≥3 infected lobes on chest imaging. Nutritional status was determined by the geriatric nutritional risk index (GNRI) and prognostic nutritional index (PNI). Inflammatory markers included monocyte-to-lymphocyte ratio (MLR), neutrophil-to-lymphocyte ratio (NLR), and systemic inflammatory response index (SII). Multivariate logistic regression, receiver operating characteristic (ROC) curves, random forest, and mediation analysis were leveraged to clarify the links of nutritional status and inflammatory response with PTB severity. Results: 337 patients were included. In the fully-adjusted logistic regression model, GNRI (OR: 0.93; 95%CI: 0.90-0.96, P<0.001) and PNI (OR: 0.90; 95%CI; 0.86-0.95, P<0.001) were independent protective factors for severe PTB, whereas NLR (OR: 1.07; 95%CI: 1.01-1.16, P<0.05) and MLR (OR: 3.11; 95%CI: 1.16-9.71, P0.05). GNRI mediated 51.64% and 60.58% of the effect of NLR and MLR on PTB, respectively. PNI mediated 70.15% and 76.70% of the effect of NLR and MLR on PTB, respectively. When NLR, MLR, GNRI, and PNI were integrated with traditional clinical indexes, the AUC increased to 0.723 (95% CI: 0.668-0.777). Conclusion: Nutrition and inflammatory response are significantly associated with PTB severity, and nutritional status mediates the effect of inflammatory response on PTB severity.
- Open Access
- 1 August 2024
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 17, 3491-3499
Contezolid for the Treatment of Drug-Resistant Tuberculosis in China: A Clinical Case Series
Background: Linezolid (LZD) is a cornerstone medication in the treatment of drug-resistant tuberculosis (DR-TB). However, it frequently triggers adverse effects such as bone marrow suppression, optic neuropathy, and peripheral neuropathy, all of which can impact treatment outcomes and prognosis. Contezolid (CZD), a novel oxazolidinone antibiotic, exhibits comparable antimicrobial efficacy against Mycobacterium tuberculosis as LZD, but with potentially enhanced safety profiles. Case Presentation: This report presents five cases (Cases 1– 5) of LZD intolerance, wherein CZD served as an effective alternative treatment. In Cases 1– 3, LZD administration resulted in bone marrow suppression, primarily manifested as anemia. Transitioning to CZD therapy led to a rise and stabilization of hemoglobin (HGB) levels in Cases 1– 2, and a return to baseline values in Case 3. In Case 4, CZD treatment alleviated symptoms of LZD-induced peripheral neuritis, although complete resolution was not achieved, hinting at potential irreversibility of this type of peripheral neuropathy. In Case 5, direct CZD anti-TB therapy was initiated for recurrent leukopenia and neutropenia, resulting in no further severe myelosuppression and successful recovery. Conclusion: These case studies suggest that CZD could represent an effective and safe option for anti-TB therapy, especially for patients intolerant to LZD.
- 1 August 2024
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 17, 3491-3499
Open AccessContezolid for the Treatment of Drug-Resistant Tuberculosis in China: A Clinical Case Series
Background: Linezolid (LZD) is a cornerstone medication in the treatment of drug-resistant tuberculosis (DR-TB). However, it frequently triggers adverse effects such as bone marrow suppression, optic neuropathy, and peripheral neuropathy, all of which can impact treatment outcomes and prognosis. Contezolid (CZD), a novel oxazolidinone antibiotic, exhibits comparable antimicrobial efficacy against Mycobacterium tuberculosis as LZD, but with potentially enhanced safety profiles. Case Presentation: This report presents five cases (Cases 1– 5) of LZD intolerance, wherein CZD served as an effective alternative treatment. In Cases 1– 3, LZD administration resulted in bone marrow suppression, primarily manifested as anemia. Transitioning to CZD therapy led to a rise and stabilization of hemoglobin (HGB) levels in Cases 1– 2, and a return to baseline values in Case 3. In Case 4, CZD treatment alleviated symptoms of LZD-induced peripheral neuritis, although complete resolution was not achieved, hinting at potential irreversibility of this type of peripheral neuropathy. In Case 5, direct CZD anti-TB therapy was initiated for recurrent leukopenia and neutropenia, resulting in no further severe myelosuppression and successful recovery. Conclusion: These case studies suggest that CZD could represent an effective and safe option for anti-TB therapy, especially for patients intolerant to LZD.
- Open Access
- 16 April 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1267624
The effects of IL-27 and IL-35 gene variation and expression levels on the susceptibility and clinical manifestations of pulmonary tuberculosis
Inflammatory cytokines have crucial roles in the pathogenesis of tuberculosis (TB), and interleukin (IL)-27 and IL-35 have a pro-inflammatory and anti-inflammatory effect on many diseases, including infectious diseases. Therefore, we evaluated the relationship between IL-27 and IL-35 gene polymorphism, expression levels, and pulmonary TB (PTB) susceptibility. Nine single-nucleotide polymorphisms (SNPs) in the IL-27 gene (rs181206, rs153109, and rs17855750) and the IL-35 gene (rs4740, rs428253, rs9807813, rs2243123, rs2243135, and rs568408) were genotyped by the SNPscan technique in 497 patients with PTB and 501 controls. There was no significant difference regarding the genotype and allele frequencies of the above SNPs in the IL-27 and IL-35 genes between patients with PTB and controls. Haplotype analysis showed that the frequency of the GAC haplotype in the IL-35 gene was significantly decreased in patients with PTB when compared to controls (p = 0.036). Stratified analysis suggested that the frequency of the IL-27 rs17855750 GG genotype was significantly increased in patients with PTB with fever. Moreover, the lower frequency of the IL-35 rs568408 GA genotype was associated with drug-induced liver injury in patients with PTB. The IL-35 rs428253 GC genotype, as well as the rs4740 AA genotype and A allele, showed significant relationships with hypoproteinemia in patients with PTB. When compared with controls, the IL-27 level was significantly increased in patients with PTB. Taken together, IL-35 gene variation might contribute to a protective role on the susceptibility to PTB, and IL-27 and IL-35 gene polymorphisms were associated with several clinical manifestations of patients with PTB.
- 16 April 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1267624
Open AccessThe effects of IL-27 and IL-35 gene variation and expression levels on the susceptibility and clinical manifestations of pulmonary tuberculosis
Inflammatory cytokines have crucial roles in the pathogenesis of tuberculosis (TB), and interleukin (IL)-27 and IL-35 have a pro-inflammatory and anti-inflammatory effect on many diseases, including infectious diseases. Therefore, we evaluated the relationship between IL-27 and IL-35 gene polymorphism, expression levels, and pulmonary TB (PTB) susceptibility. Nine single-nucleotide polymorphisms (SNPs) in the IL-27 gene (rs181206, rs153109, and rs17855750) and the IL-35 gene (rs4740, rs428253, rs9807813, rs2243123, rs2243135, and rs568408) were genotyped by the SNPscan technique in 497 patients with PTB and 501 controls. There was no significant difference regarding the genotype and allele frequencies of the above SNPs in the IL-27 and IL-35 genes between patients with PTB and controls. Haplotype analysis showed that the frequency of the GAC haplotype in the IL-35 gene was significantly decreased in patients with PTB when compared to controls (p = 0.036). Stratified analysis suggested that the frequency of the IL-27 rs17855750 GG genotype was significantly increased in patients with PTB with fever. Moreover, the lower frequency of the IL-35 rs568408 GA genotype was associated with drug-induced liver injury in patients with PTB. The IL-35 rs428253 GC genotype, as well as the rs4740 AA genotype and A allele, showed significant relationships with hypoproteinemia in patients with PTB. When compared with controls, the IL-27 level was significantly increased in patients with PTB. Taken together, IL-35 gene variation might contribute to a protective role on the susceptibility to PTB, and IL-27 and IL-35 gene polymorphisms were associated with several clinical manifestations of patients with PTB.
- Open Access
- 7 December 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1011700
Clinical relevance of genetic polymorphisms in WNT signaling pathway (SFRP1, WNT3A, CTNNB1, WIF-1, DKK-1, LRP5, LRP6) on pulmonary tuberculosis in a Chinese population
The present study was performed to evaluate the association of WNT signaling pathway genes variants with pulmonary tuberculosis (PTB) risk in Chinese Han population. Our study subjects were composed of 452 PTB patients and 465 normal controls, and seventeen SNPs of seven genes in WNT signaling pathway (SFRP1, WNT3A, CTNNB1, WIF-1, DKK-1, LRP5, LRP6) were genotyped by SNPscan technique. We found no significant relationship of SFRP1 rs10088390, rs4736958, rs3242, WNT3A rs752107, rs3121310, CTNNB1 rs2293303, rs1798802, rs4135385, WIF-1 rs1026024, rs3782499, DKK-1 rs2241529, rs1569198, LRP5 rs3736228, rs556442, LRP6 rs2302685, rs11054697, rs10743980 polymorphisms with PTB susceptibility. While, WIF-1 rs3782499 variant was associated with susceptibility to PTB under recessive model, and haplotype analysis showed that DKK-1 GA haplotype frequency was significantly increased in PTB patients. The WNT3A rs3121310, CTNNB1 rs2293303 polymorphisms were respectively associated with drug-induced liver injury (DILI), sputum smear-positive in PTB patients. The rs3782499 in WIF-1 gene was related to fever, leukopenia, and the rs1569198 in DKK-1 was linked to sputum smear-positive in PTB patients. In LRP5 gene, rs3736228, rs556442 variants respectively affected the occurrence of DILI, fever, and LRP6 gene rs2302685, rs10743980 variants respectively influenced the development of hypoproteinemia, sputum smear-positive in PTB patients. Our results revealed that WNT signaling pathway genes variation were not associated with the susceptibility to PTB, while WNT3A, CTNNB1, WIF-1, DKK-1, LRP5, LRP6 genetic variations might be closely related to the occurrence of several clinical characteristics of PTB patients.
- 7 December 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1011700
Open AccessClinical relevance of genetic polymorphisms in WNT signaling pathway (SFRP1, WNT3A, CTNNB1, WIF-1, DKK-1, LRP5, LRP6) on pulmonary tuberculosis in a Chinese population
The present study was performed to evaluate the association of WNT signaling pathway genes variants with pulmonary tuberculosis (PTB) risk in Chinese Han population. Our study subjects were composed of 452 PTB patients and 465 normal controls, and seventeen SNPs of seven genes in WNT signaling pathway (SFRP1, WNT3A, CTNNB1, WIF-1, DKK-1, LRP5, LRP6) were genotyped by SNPscan technique. We found no significant relationship of SFRP1 rs10088390, rs4736958, rs3242, WNT3A rs752107, rs3121310, CTNNB1 rs2293303, rs1798802, rs4135385, WIF-1 rs1026024, rs3782499, DKK-1 rs2241529, rs1569198, LRP5 rs3736228, rs556442, LRP6 rs2302685, rs11054697, rs10743980 polymorphisms with PTB susceptibility. While, WIF-1 rs3782499 variant was associated with susceptibility to PTB under recessive model, and haplotype analysis showed that DKK-1 GA haplotype frequency was significantly increased in PTB patients. The WNT3A rs3121310, CTNNB1 rs2293303 polymorphisms were respectively associated with drug-induced liver injury (DILI), sputum smear-positive in PTB patients. The rs3782499 in WIF-1 gene was related to fever, leukopenia, and the rs1569198 in DKK-1 was linked to sputum smear-positive in PTB patients. In LRP5 gene, rs3736228, rs556442 variants respectively affected the occurrence of DILI, fever, and LRP6 gene rs2302685, rs10743980 variants respectively influenced the development of hypoproteinemia, sputum smear-positive in PTB patients. Our results revealed that WNT signaling pathway genes variation were not associated with the susceptibility to PTB, while WNT3A, CTNNB1, WIF-1, DKK-1, LRP5, LRP6 genetic variations might be closely related to the occurrence of several clinical characteristics of PTB patients.